Scientific Publications

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

American Society of Hematology Annual Meeting, Ghobadi et al, December 2023

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Science Translational Medicine, Berrien-Elliot et al, February 2022

Memory-like differentiation enhances NK cell responses to melanoma

Clin Cancer Res, Marin et al, June 2021

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Cancer Discovery, Berrien-Elliott et al, December 2020

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, Gang et al, November 2020 

Memory-like natural killer cells for cancer immunotherapy

Seminars in Hematology, Gang et al, November 2020 

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Leukemia, Cooper et al, February 2018

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses

Biol Blood Marrow Transplant, Wagner et al, March 2017 

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Science Translational Medicine, Romee et al, September 2016

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Biol Blood Marrow Transplant, Leong et al, April 2014

Cytokine activation induces human memory-like NK cells.

Blood, Romee et al, December 2012

Latest News

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of …

Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007

— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, …

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic …

ST. LOUIS

4260 Forest Park Ave
Suite 100
St. Louis, MO 63108
(636) 385-5306

SOCIAL

Copyright © 2025 Wugen. All Rights Reserved.

Privacy Notice
a COGNEO design